Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Reviews in Endocrine and Metabolic Disorders
Erschienen in: Reviews in Endocrine and Metabolic Disorders 4/2020

26.08.2020 | Obesity

Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation

verfasst von: Han Xie, Natesh Yepuri, Qinghe Meng, Ravi Dhawan, Colin A. Leech, Oleg G. Chepurny, George G. Holz, Robert N. Cooney

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

The cholinergic anti-inflammatory reflex (CAIR) represents an important homeostatic regulatory mechanism for sensing and controlling the body’s response to inflammatory stimuli. Vagovagal reflexes are an integral component of CAIR whose anti-inflammatory effects are mediated by acetylcholine (ACh) acting at α7 nicotinic acetylcholine receptors (α7nAChR) located on cells of the immune system. Recently, it is appreciated that CAIR and α7nAChR also participate in the control of metabolic homeostasis. This has led to the understanding that defective vagovagal reflex circuitry underlying CAIR might explain the coexistence of obesity, diabetes, and inflammation in the metabolic syndrome. Thus, there is renewed interest in the α7nAChR that mediates CAIR, particularly from the standpoint of therapeutics. Of special note is the recent finding that α7nAChR agonist GTS-21 acts at L-cells of the distal intestine to stimulate the release of two glucoregulatory and anorexigenic hormones: glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Furthermore, α7nAChR agonist PNU 282987 exerts trophic factor-like actions to support pancreatic β-cell survival under conditions of stress resembling diabetes. This review provides an overview of α7nAChR function as it pertains to CAIR, vagovagal reflexes, and metabolic homeostasis. We also consider the possible usefulness of α7nAChR agonists for treatment of obesity, diabetes, and inflammation.
Literatur
1.
2.
Wu J, Jiao ZY, Zhang Z, Tang ZH, Zhang HH, Lu HL, et al. Cross-talk between alpha7 nAChR-mediated cholinergic pathway and acylation stimulating protein signaling in 3T3-L1 adipocytes: role of NFkappaB and STAT3. Biochem Cell Biol. 2015;93(4):335–42.PubMedCrossRef
3.
Cancello R, Zulian A, Maestrini S, Mencarelli M, Della Barba A, Invitti C, et al. The nicotinic acetylcholine receptor alpha7 in subcutaneous mature adipocytes: downregulation in human obesity and modulation by diet-induced weight loss. Int J Obes. 2012;36(12):1552–7.CrossRef
4.
Xu TY, Guo LL, Wang P, Song J, Le YY, Viollet B, et al. Chronic exposure to nicotine enhances insulin sensitivity through alpha7 nicotinic acetylcholine receptor-STAT3 pathway. PLoS One. 2012;7(12):e51217.PubMedPubMedCentralCrossRef
5.
Scabia G, Cancello R, Dallanoce C, Berger S, Matera C, Dattilo A, et al. ICH3, a selective alpha7 nicotinic acetylcholine receptor agonist, modulates adipocyte inflammation associated with obesity. J Endocrinol Investig. 2020;43(7):983–93.CrossRef
6.
Wada T, Naito M, Kenmochi H, Tsuneki H, Sasaoka T. Chronic nicotine exposure enhances insulin-induced mitogenic signaling via up-regulation of alpha7 nicotinic receptors in isolated rat aortic smooth muscle cells. Endocrinology. 2007;148(2):790–9.PubMedCrossRef
7.
Zhao J, Park S, Kim JW, Qi J, Zhou Z, Lim CW, et al. Nicotine attenuates concanavalin A-induced liver injury in mice by regulating the alpha7-nicotinic acetylcholine receptor in Kupffer cells. Int Immunopharmacol. 2020;78:106071.PubMedCrossRef
8.
Hiramoto T, Chida Y, Sonoda J, Yoshihara K, Sudo N, Kubo C. The hepatic vagus nerve attenuates Fas-induced apoptosis in the mouse liver via alpha7 nicotinic acetylcholine receptor. Gastroenterology. 2008;134(7):2122–31.PubMedCrossRef
9.
Souza CM, do Amaral CL, Souza SC, ACP d S, de Cássia Alves Martins I, Contieri LS, et al. JAK2/STAT3 pathway is required for α7nAChR-dependent expression of POMC and AGRP neuropeptides in male mice. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 2019;53(4):701–12.CrossRef
10.
Gupta D, Lacayo AA, Greene SM, Leahy JL, Jetton TL. Beta-cell mass restoration by alpha7 nicotinic acetylcholine receptor activation. J Biol Chem. 2018;293(52):20295–306.PubMedPubMedCentralCrossRef
11.
Wang D, Meng Q, Leech CA, Yepuri N, Zhang L, Holz GG, et al. alpha7 nicotinic acetylcholine receptor regulates the function and viability of L cells. Endocrinology. 2018;159(9):3132–42.PubMedPubMedCentralCrossRef
12.
Stegemann A, Bohm M. Tropisetron via alpha7 nicotinic acetylcholine receptor suppresses tumor necrosis factor-alpha-mediated cell responses of human keratinocytes. Exp Dermatol. 2019;28(3):276–82.PubMedCrossRef
13.
Marrero MB, Lucas R, Salet C, Hauser TA, Mazurov A, Lippiello PM, et al. An alpha7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J Pharmacol Exp Ther. 2010;332(1):173–80.PubMedCrossRef
14.
Wang X, Yang Z, Xue B, Shi H. Activation of the cholinergic antiinflammatory pathway ameliorates obesity-induced inflammation and insulin resistance. Endocrinology. 2011;152(3):836–46.PubMedPubMedCentralCrossRef
15.
Liu RH, Kurose T, Matsukura S. Oral nicotine administration decreases tumor necrosis factor-alpha expression in fat tissues in obese rats. Metabolism. 2001;50(1):79–85.PubMedCrossRef
16.
17.
Chang EH, Chavan SS, Pavlov VA. Cholinergic control of inflammation, metabolic dysfunction, and cognitive impairment in obesity-associated disorders: mechanisms and novel therapeutic opportunities. Front Neurosci. 2019;13:263.PubMedPubMedCentralCrossRef
18.
Berthoud HR, Neuhuber WL. Vagal mechanisms as neuromodulatory targets for the treatment of metabolic disease. Ann N Y Acad Sci. 2019;1454(1):42–55.PubMedPubMedCentralCrossRef
19.
Bonaz B, Sinniger V, Pellissier S. The vagus nerve in the neuro-immune axis: implications in the pathology of the gastrointestinal tract. Front Immunol. 2017;8:1452.PubMedPubMedCentralCrossRef
20.
Browning KN, Verheijden S, Boeckxstaens GE. The vagus nerve in appetite regulation, mood, and intestinal inflammation. Gastroenterology. 2017;152(4):730–44.PubMedCrossRef
21.
22.
Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci. 2019;20(23).
23.
Johnston GR, Webster NR. Cytokines and the immunomodulatory function of the vagus nerve. Br J Anaesth. 2009;102(4):453–62.PubMedCrossRef
24.
Rosas-Ballina M, Goldstein RS, Gallowitsch-Puerta M, Yang L, Valdés-Ferrer SI, Patel NB, et al. The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol Med. 2009;15(7–8):195–202.PubMedPubMedCentralCrossRef
25.
Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421(6921):384–8.PubMedCrossRef
26.
Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, et al. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol. 2006;146(1):116–23.PubMedPubMedCentralCrossRef
27.
Masi EB, Valdes-Ferrer SI, Steinberg BE. The vagus neurometabolic interface and clinical disease. Int J Obes. 2018;42(6):1101–11.CrossRef
28.
29.
Goehler LE, Gaykema RP, Nguyen KT, Lee JE, Tilders FJ, Maier SF, et al. Interleukin-1beta in immune cells of the abdominal vagus nerve: a link between the immune and nervous systems? J Neurosci. 1999;19(7):2799–806.PubMedPubMedCentralCrossRef
30.
Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405(6785):458–62.PubMedCrossRef
31.
Rosas-Ballina M, Olofsson PS, Ochani M, Valdes-Ferrer SI, Levine YA, Reardon C, et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science. 2011;334(6052):98–101.PubMedPubMedCentralCrossRef
32.
Abot A, Cani PD, Knauf C. Impact of intestinal peptides on the enteric nervous system: novel approaches to control glucose metabolism and food intake. Front Endocrinol. 2018;9:328.CrossRef
33.
Nezami BG, Srinivasan S. Enteric nervous system in the small intestine: pathophysiology and clinical implications. Curr Gastroenterol Rep. 2010;12(5):358–65.PubMedPubMedCentralCrossRef
34.
Metz CN, Pavlov VA. Vagus nerve cholinergic circuitry to the liver and the gastrointestinal tract in the neuroimmune communicatome. Am J Physiol Gastrointest Liver Physiol. 2018;315(5):G651–g8.PubMedPubMedCentralCrossRef
35.
Jamal Uddin M, Joe Y, Zheng M, Blackshear PJ, Ryter SW, Park JW, et al. A functional link between heme oxygenase-1 and tristetraprolin in the anti-inflammatory effects of nicotine. Free Radic Biol Med. 2013;65:1331–9.PubMedCrossRef
36.
Ahren B, Taborsky GJ Jr. The mechanism of vagal nerve stimulation of glucagon and insulin secretion in the dog. Endocrinology. 1986;118(4):1551–7.PubMedCrossRef
37.
38.
Bugajski AJ, Gil K, Ziomber A, Zurowski D, Zaraska W, Thor PJ. Effect of long-term vagal stimulation on food intake and body weight during diet induced obesity in rats. J Physiol Pharmacol. 2007;58(Suppl 1):5–12.PubMed
39.
Burneo JG, Faught E, Knowlton R, Morawetz R, Kuzniecky R. Weight loss associated with vagus nerve stimulation. Neurology. 2002;59(3):463–4.PubMedCrossRef
40.
Dai F, Yin J, Chen JDZ. Effects and mechanisms of vagal nerve stimulation on body weight in diet-induced obese rats. Obes Surg. 2020;30(3):948–56.PubMedCrossRef
41.
de Lartigue G, Diepenbroek C. Novel developments in vagal afferent nutrient sensing and its role in energy homeostasis. Curr Opin Pharmacol. 2016;31:38–43.PubMedPubMedCentralCrossRef
42.
Li S, Zhai X, Rong P, McCabe MF, Wang X, Zhao J, et al. Therapeutic effect of vagus nerve stimulation on depressive-like behavior, hyperglycemia and insulin receptor expression in Zucker fatty rats. PLoS One. 2014;9(11):e112066.PubMedPubMedCentralCrossRef
43.
Malbert CH, Picq C, Divoux JL, Henry C, Horowitz M. Obesity-associated alterations in glucose metabolism are reversed by chronic bilateral stimulation of the abdominal vagus nerve. Diabetes. 2017;66(4):848–57.PubMedCrossRef
44.
Pardo JV, Sheikh SA, Kuskowski MA, Surerus-Johnson C, Hagen MC, Lee JT, et al. Weight loss during chronic, cervical vagus nerve stimulation in depressed patients with obesity: an observation. Int J Obes. 2007;31(11):1756–9.CrossRef
45.
Sobocki J, Fourtanier G, Estany J, Otal P. Does vagal nerve stimulation affect body composition and metabolism? Experimental study of a new potential technique in bariatric surgery. Surgery. 2006;139(2):209–16.PubMedCrossRef
46.
Val-Laillet D, Biraben A, Randuineau G, Malbert CH. Chronic vagus nerve stimulation decreased weight gain, food consumption and sweet craving in adult obese minipigs. Appetite. 2010;55(2):245–52.PubMedCrossRef
47.
Arterburn DE, Fisher DP. The current state of the evidence for bariatric surgery. Jama. 2014;312(9):898–9.PubMedCrossRef
48.
Ikramuddin S, Blackstone RP, Brancatisano A, Toouli J, Shah SN, Wolfe BM, et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. JAMA. 2014;312(9):915–22.PubMedCrossRef
49.
Priest C, Tontonoz P. Inter-organ cross-talk in metabolic syndrome. Nat Metab. 2019;1(12):1177–88.PubMedCrossRef
50.
Burcelin R, Gourdy P. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. Obes Rev. 2017;18(1):86–98.PubMedCrossRef
51.
52.
53.
Kentish SJ, Vincent AD, Kennaway DJ, Wittert GA, Page AJ. High-fat diet-induced obesity ablates gastric vagal afferent circadian rhythms. J Neurosci. 2016;36(11):3199–207.PubMedPubMedCentralCrossRef
54.
Kentish S, Li H, Philp LK, O'Donnell TA, Isaacs NJ, Young RL, et al. Diet-induced adaptation of vagal afferent function. J Physiol. 2012;590(1):209–21.PubMedCrossRef
55.
Daly DM, Park SJ, Valinsky WC, Beyak MJ. Impaired intestinal afferent nerve satiety signalling and vagal afferent excitability in diet induced obesity in the mouse. J Physiol. 2011;589(Pt 11):2857–70.PubMedPubMedCentralCrossRef
56.
Kentish SJ, O'Donnell TA, Isaacs NJ, Young RL, Li H, Harrington AM, et al. Gastric vagal afferent modulation by leptin is influenced by food intake status. J Physiol. 2013;591(7):1921–34.PubMedCrossRef
57.
Lee J, Cummings BP, Martin E, Sharp JW, Graham JL, Stanhope KL, et al. Glucose sensing by gut endocrine cells and activation of the vagal afferent pathway is impaired in a rodent model of type 2 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol. 2012;302(6):R657–66.PubMedCrossRef
58.
Bernik TR, Friedman SG, Ochani M, DiRaimo R, Ulloa L, Yang H, et al. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med. 2002;195(6):781–8.PubMedPubMedCentralCrossRef
59.
Beinat C, Banister SD, Herrera M, Law V, Kassiou M. The therapeutic potential of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. CNS Drugs. 2015;29(7):529–42.PubMedCrossRef
60.
Ishikawa M, Hashimoto K. α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia. Curr Pharm Des. 2011;17(2):121–9.PubMedCrossRef
61.
62.
Terry AV Jr, Callahan PM. α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: update on animal and clinical studies and strategies for the future. Neuropharmacology. 2020;170:108053.PubMedCrossRefPubMedCentral
63.
Chini B, Raimond E, Elgoyhen AB, Moralli D, Balzaretti M, Heinemann S. Molecular cloning and chromosomal localization of the human alpha 7-nicotinic receptor subunit gene (CHRNA7). Genomics. 1994;19(2):379–81.PubMedCrossRef
64.
Orr-Urtreger A, Seldin MF, Baldini A, Beaudet AL. Cloning and mapping of the mouse alpha 7-neuronal nicotinic acetylcholine receptor. Genomics. 1995;26(2):399–402.PubMedCrossRef
65.
Peng X, Katz M, Gerzanich V, Anand R, Lindstrom J. Human alpha 7 acetylcholine receptor: cloning of the alpha 7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional alpha 7 homomers expressed in Xenopus oocytes. Mol Pharmacol. 1994;45(3):546–54.PubMed
66.
Séguéla P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci. 1993;13(2):596–604.PubMedPubMedCentralCrossRef
67.
Changeux JP. The nicotinic acetylcholine receptor: the founding father of the pentameric ligand-gated ion channel superfamily. J Biol Chem. 2012;287(48):40207–15.PubMedPubMedCentralCrossRef
68.
Kalamida D, Poulas K, Avramopoulou V, Fostieri E, Lagoumintzis G, Lazaridis K, et al. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. FEBS J. 2007;274(15):3799–845.PubMedCrossRef
69.
Andersen N, Corradi J, Sine SM, Bouzat C. Stoichiometry for activation of neuronal alpha7 nicotinic receptors. Proc Natl Acad Sci U S A. 2013;110(51):20819–24.PubMedPubMedCentralCrossRef
70.
Nielsen BE, Minguez T, Bermudez I, Bouzat C. Molecular function of the novel alpha7beta2 nicotinic receptor. Cellular and Molecular Life Sciences : CMLS. 2018;75(13):2457–71.PubMedCrossRef
71.
72.
Uteshev VV. alpha7 nicotinic ACh receptors as a ligand-gated source of Ca2+ ions: the search for a Ca2+ optimum. Adv Exp Med Biol. 2012;740:603–38.PubMedPubMedCentralCrossRef
73.
Corradi J, Bouzat C. Understanding the bases of function and modulation of α7 nicotinic receptors: implications for drug discovery. Mol Pharmacol. 2016;90(3):288–99.PubMedCrossRef
74.
King JR, Ullah A, Bak E, Jafri MS, Kabbani N. Ionotropic and metabotropic mechanisms of allosteric modulation of α7 nicotinic receptor intracellular calcium. Mol Pharmacol. 2018;93(6):601–11.CrossRefPubMed
75.
Liu Q, Berg DK. Actin filaments and the opposing actions of CaM kinase II and calcineurin in regulating alpha7-containing nicotinic receptors on chick ciliary ganglion neurons. J Neurosci. 1999;19(23):10280–8.PubMedPubMedCentralCrossRef
76.
King JR, Nordman JC, Bridges SP, Lin MK, Kabbani N. Identification and characterization of a G protein-binding cluster in α7 nicotinic acetylcholine receptors. J Biol Chem. 2015;290(33):20060–70.PubMedPubMedCentralCrossRef
77.
Grady SR, Wageman CR, Patzlaff NE, Marks MJ. Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include alpha5 or alpha6 subunits and that mediate synaptosomal neurotransmitter release. Neuropharmacology. 2012;62(5–6):1935–43.PubMedPubMedCentralCrossRef
78.
Mao D, Yasuda RP, Fan H, Wolfe BB, Kellar KJ. Heterogeneity of nicotinic cholinergic receptors in rat superior cervical and nodose ganglia. Mol Pharmacol. 2006;70(5):1693–9.PubMedCrossRef
79.
Simeone X, Karch R, Ciuraszkiewicz A, Orr-Urtreger A, Lemmens-Gruber R, Scholze P, et al. The role of the nAChR subunits α5, β2, and β4 on synaptic transmission in the mouse superior cervical ganglion. Physiol Rep. 2019;7(6):e14023.PubMedPubMedCentralCrossRef
80.
Orr-Urtreger A, Göldner FM, Saeki M, Lorenzo I, Goldberg L, De Biasi M, et al. Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci. 1997;17(23):9165–71.PubMedPubMedCentralCrossRef
81.
Gulsevin A, Papke RL, Horenstein N. In silico modeling of the α7 nicotinic acetylcholine receptor: new pharmacological challenges associated with multiple modes of signaling. Mini Rev Med Chem. 2020;20(10):841–64.PubMedCrossRefPubMedCentral
82.
Kem WR. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000;113(1–2):169–81.PubMedCrossRef
83.
Papke RL, Lindstrom JM. Nicotinic acetylcholine receptors: conventional and unconventional ligands and signaling. Neuropharmacology. 2020;168:108021.PubMedCrossRefPubMedCentral
84.
Williams DK, Wang J, Papke RL. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem Pharmacol. 2011;82(8):915–30.PubMedPubMedCentralCrossRef
85.
Meyer EM, Kuryatov A, Gerzanich V, Lindstrom J, Papke RL. Analysis of 3-(4-hydroxy, 2-Methoxybenzylidene)anabaseine selectivity and activity at human and rat alpha-7 nicotinic receptors. J Pharmacol Exp Ther. 1998;287(3):918–25.PubMed
86.
Bodnar AL, Cortes-Burgos LA, Cook KK, Dinh DM, Groppi VE, Hajos M, et al. Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. J Med Chem. 2005;48(4):905–8.PubMedCrossRef
87.
Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, et al. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. J Med Chem. 2006;49(14):4425–36.PubMedCrossRef
88.
Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, et al. Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg Med Chem Lett. 2008;18(12):3611–5.PubMedCrossRef
89.
Dallanoce C, Magrone P, Matera C, Frigerio F, Grazioso G, De Amici M, et al. Design, synthesis, and pharmacological characterization of novel spirocyclic quinuclidinyl-Delta2-isoxazoline derivatives as potent and selective agonists of alpha7 nicotinic acetylcholine receptors. ChemMedChem. 2011;6(5):889–903.PubMedCrossRef
90.
Matera C, Dondio G, Braida D, Ponzoni L, De Amici M, Sala M, et al. In vivo and in vitro ADMET profiling and in vivo pharmacodynamic investigations of a selective alpha7 nicotinic acetylcholine receptor agonist with a spirocyclic Delta(2)-isoxazoline molecular skeleton. Eur J Pharmacol. 2018;820:265–73.PubMedCrossRef
91.
Di Cesare ML, Pacini A, Matera C, Zanardelli M, Mello T, De Amici M, et al. Involvement of alpha7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation. Neuropharmacology. 2014;79:37–48.CrossRef
92.
Briggs CA, Gronlien JH, Curzon P, Timmermann DB, Ween H, Thorin-Hagene K, et al. Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors. Br J Pharmacol. 2009;158(6):1486–94.PubMedPubMedCentralCrossRef
93.
Bristow LJ, Easton AE, Li YW, Sivarao DV, Lidge R, Jones KM, et al. The novel, nicotinic alpha7 receptor partial agonist, BMS-933043, improves cognition and sensory processing in preclinical models of schizophrenia. PLoS One. 2016;11(7):e0159996.PubMedPubMedCentralCrossRef
94.
Godin JR, Roy P, Quadri M, Bagdas D, Toma W, Narendrula-Kotha R, et al. A silent agonist of alpha7 nicotinic acetylcholine receptors modulates inflammation ex vivo and attenuates EAE. Brain Behav Immun. 2020;87:286–300.PubMedCrossRef
95.
Gronlien JH, Hakerud M, Ween H, Thorin-Hagene K, Briggs CA, Gopalakrishnan M, et al. Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol. 2007;72(3):715–24.PubMedCrossRef
96.
Gurley DA, Lanthorn TH. Nicotinic agonists competitively antagonize serotonin at mouse 5-HT3 receptors expressed in Xenopus oocytes. Neurosci Lett. 1998;247(2–3):107–10.PubMedCrossRef
97.
Gault J, Robinson M, Berger R, Drebing C, Logel J, Hopkins J, et al. Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics. 1998;52(2):173–85.PubMedCrossRef
98.
Riley B, Williamson M, Collier D, Wilkie H, Makoff A. A 3-Mb map of a large segmental duplication overlapping the alpha7-nicotinic acetylcholine receptor gene (CHRNA7) at human 15q13-q14. Genomics. 2002;79(2):197–209.PubMedCrossRef
99.
Araud T, Graw S, Berger R, Lee M, Neveu E, Bertrand D, et al. The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of alpha7*nAChR function. Biochem Pharmacol. 2011;82(8):904–14.PubMedPubMedCentralCrossRef
100.
de Lucas-Cerrillo AM, Maldifassi MC, Arnalich F, Renart J, Atienza G, Serantes R, et al. Function of partially duplicated human α77 nicotinic receptor subunit CHRFAM7A gene: potential implications for the cholinergic anti-inflammatory response. J Biol Chem. 2011;286(1):594–606.PubMedCrossRef
101.
Baez-Pagan CA, Delgado-Velez M, Lasalde-Dominicci JA. Activation of the macrophage alpha7 nicotinic acetylcholine receptor and control of inflammation. J NeuroImmune Pharmacol. 2015;10(3):468–76.PubMedPubMedCentralCrossRef
102.
de Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, Bennink RJ, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol. 2005;6(8):844–51.PubMedCrossRef
103.
Marrero MB, Bencherif M. Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB. Brain Res. 2009;1256:1–7.PubMedCrossRef
104.
Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132(6):2169–80.PubMedCrossRef
105.
Han JM, Levings MK. Immune regulation in obesity-associated adipose inflammation. J Immunol. 2013;191(2):527–32.PubMedCrossRef
106.
Sutherland JP, McKinley B, Eckel RH. The metabolic syndrome and inflammation. Metab Syndr Relat Disord. 2004;2(2):82–104.PubMedCrossRef
107.
Phosat C, Panprathip P, Chumpathat N, Prangthip P, Chantratita N, Soonthornworasiri N, et al. Elevated C-reactive protein, interleukin 6, tumor necrosis factor alpha and glycemic load associated with type 2 diabetes mellitus in rural Thais: a cross-sectional study. BMC Endocr Disord. 2017;17(1):44.PubMedPubMedCentralCrossRef
108.
109.
Rehman K, Akash MS. Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci. 2016;23(1):87.PubMedPubMedCentralCrossRef
110.
Tzanavari T, Giannogonas P, Karalis KP. TNF-alpha and obesity. Curr Dir Autoimmun. 2010;11:145–56.PubMedCrossRef
111.
112.
Jiao ZY, Wu J, Liu C, Wen B, Zhao WZ, Du XL. Nicotinic α7 receptor inhibits the acylation stimulating protein-induced production of monocyte chemoattractant protein-1 and keratinocyte-derived chemokine in adipocytes by modulating the p38 kinase and nuclear factor-κB signaling pathways. Mol Med Rep. 2016;14(4):2959–66.PubMedPubMedCentralCrossRef
113.
Chau YY, Bandiera R, Serrels A, Martínez-Estrada OM, Qing W, Lee M, et al. Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source. Nat Cell Biol. 2014;16(4):367–75.PubMedPubMedCentralCrossRef
114.
Hasan MK, Friedman TC, Sims C, Lee DL, Espinoza-Derout J, Ume A, et al. alpha7-nicotinic acetylcholine receptor agonist ameliorates nicotine plus high-fat diet-induced hepatic steatosis in male mice by inhibiting oxidative stress and stimulating AMPK signaling. Endocrinology. 2018;159(2):931–44.PubMedCrossRef
115.
Li DJ, Zhao T, Xin RJ, Wang YY, Fei YB, Shen FM. Activation of alpha7 nicotinic acetylcholine receptor protects against oxidant stress damage through reducing vascular peroxidase-1 in a JNK signaling-dependent manner in endothelial cells. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 2014;33(2):468–78.CrossRef
116.
Costa SO, Souza CM, Lanza PG, Sartori JO, Ignacio-Souza LM, Candreva T, et al. Maternal high fat diet consumption reduces liver alpha7 nicotinic cholinergic receptor expression and impairs insulin signalling in the offspring. Sci Rep. 2020;10(1):48.PubMedPubMedCentralCrossRef
117.
Zhu Z, Cao F, Li X. Epigenetic programming and fetal metabolic programming. Front Endocrinol. 2019;10:764.CrossRef
118.
Lilienfeld S. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002;8(2):159–76.PubMedPubMedCentralCrossRef
119.
Consolim-Colombo FM, Sangaleti CT, Costa FO, Morais TL, Lopes HF, Motta JM, et al. Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial. JCI Insight. 2017;2(14).
120.
121.
Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease. Biol Psychiatry. 2001;49(3):279–88.PubMedCrossRef
122.
Texidó L, Ros E, Martín-Satué M, López S, Aleu J, Marsal J, et al. Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity. Br J Pharmacol. 2005;145(5):672–8.PubMedPubMedCentralCrossRef
123.
Satapathy SK, Ochani M, Dancho M, Hudson LK, Rosas-Ballina M, Valdes-Ferrer SI, et al. Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. Mol Med. 2011;17(7–8):599–606.PubMedPubMedCentralCrossRef
124.
125.
Winders SE, Grunberg NE. Effects of nicotine on body weight, food consumption and body composition in male rats. Life Sci. 1990;46(21):1523–30.PubMedCrossRef
126.
127.
Tuesta LM, Chen Z, Duncan A, Fowler CD, Ishikawa M, Lee BR, et al. GLP-1 acts on habenular avoidance circuits to control nicotine intake. Nat Neurosci. 2017;20(5):708–16.PubMedPubMedCentralCrossRef
128.
Barrea L, Pugliese G, Muscogiuri G, Laudisio D, Colao A, Savastano S. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. Minerva Endocrinol. 2020;45(2):127–37.PubMedCrossRef
129.
Khalil H, Ellwood L, Lord H, Fernandez R. Pharmacological treatment for obesity in adults: an umbrella review. Ann Pharmacother. 2020;54(7):691–705.PubMedCrossRef
130.
Montan PD, Sourlas A, Olivero J, Silverio D, Guzman E, Kosmas CE. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Ann Transl Med. 2019;7(16):393.PubMedPubMedCentralCrossRef
131.
Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.PubMedCrossRef
132.
Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–9.PubMedPubMedCentralCrossRef
133.
Borner T, Workinger JL, Tinsley IC, Fortin SM, Stein LM, Chepurny OG, et al. Corrination of a GLP-1 receptor agonist for glycemic control without emesis. Cell Rep. 2020;31(11):107768.PubMedPubMedCentralCrossRef
134.
Mietlicki-Baase EG, Liberini CG, Workinger JL, Bonaccorso RL, Borner T, Reiner DJ, et al. A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents. Diabetes Obes Metab. 2018;20(5):1223–34.PubMedPubMedCentralCrossRef
135.
Gribble FM, Reimann F. Enteroendocrine cells: chemosensors in the intestinal epithelium. Annu Rev Physiol. 2016;78:277–99.PubMedCrossRef
136.
Gribble FM, Reimann F. Function and mechanisms of enteroendocrine cells and gut hormones in metabolism. Nat Rev Endocrinol. 2019;15(4):226–37.PubMedCrossRef
137.
138.
Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab. 2008;8(6):532–9.PubMedPubMedCentralCrossRef
139.
Ye L, Liddle RA. Gastrointestinal hormones and the gut connectome. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):9–14.PubMedPubMedCentral
140.
De Silva A, Bloom SR. Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver. 2012;6(1):10–20.PubMedPubMedCentralCrossRef
141.
Sandoval D, Dunki-Jacobs A, Sorrell J, Seeley RJ, D’Alessio DD. Impact of intestinal electrical stimulation on nutrient-induced GLP-1 secretion in vivo. Neurogastroenterol Motil. 2013;25(8):700–5.PubMedPubMedCentralCrossRef
142.
Yin J, Ji F, Gharibani P, Chen JD. Vagal nerve stimulation for glycemic control in a rodent model of type 2 diabetes. Obes Surg. 2019;29:2869–77.PubMedCrossRef
143.
Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology. 1999;140(4):1687–94.PubMedCrossRef
144.
Jorsal T, Rhee NA, Pedersen J, Wahlgren CD, Mortensen B, Jepsen SL, et al. Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. Diabetologia. 2018;61(2):284–94.PubMedCrossRef
145.
146.
Burcelin R, Gourdy P, Dalle S. GLP-1-based strategies: a physiological analysis of differential mode of action. Physiology (Bethesda). 2014;29(2):108–21.
147.
Smith EP, An Z, Wagner C, Lewis AG, Cohen EB, Li B, et al. The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 2014;19(6):1050–7.PubMedPubMedCentralCrossRef
148.
O'Malley TJ, Fava GE, Zhang Y, Fonseca VA, Wu H. Progressive change of intra-islet GLP-1 production during diabetes development. Diabetes Metab Res Rev. 2014;30(8):661–8.PubMedPubMedCentralCrossRef
149.
150.
Urusova IA, Farilla L, Hui H, D'Amico E, Perfetti R. GLP-1 inhibition of pancreatic islet cell apoptosis. Trends Endocrinol Metab. 2004;15(1):27–33.PubMedCrossRef
151.
Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144(12):5149–58.PubMedCrossRef
152.
Leech CA, Dzhura I, Chepurny OG, Kang G, Schwede F, Genieser HG, et al. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. Prog Biophys Mol Biol. 2011;107(2):236–47.PubMedPubMedCentralCrossRef
153.
Holz GG IV, Kühtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature. 1993;361(6410):362–5.PubMedPubMedCentralCrossRef
154.
Holz GG, Chepurny OG. Diabetes outfoxed by GLP-1? Sci STKE 2005;2005(268):pe2.
155.
Chepurny OG, Hussain MA, Holz GG. Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220. Endocrinology. 2002;143(6):2303–13.PubMedCrossRef
156.
157.
Gilon P, Henquin JC. Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocr Rev. 2001;22(5):565–604.PubMed
158.
Moullé VS, Tremblay C, Castell AL, Vivot K, Ethier M, Fergusson G, et al. The autonomic nervous system regulates pancreatic β-cell proliferation in adult male rats. Am J Physiol Endocrinol Metab. 2019;317(2):E234–e43.PubMedPubMedCentralCrossRef
159.
Ahrén B, Holst JJ. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes. 2001;50(5):1030–8.PubMedCrossRef
160.
Ahrén B. Autonomic regulation of islet hormone secretion--implications for health and disease. Diabetologia. 2000;43(4):393–410.PubMedCrossRef
161.
Rodriguez-Diaz R, Abdulreda MH, Formoso AL, Gans I, Ricordi C, Berggren PO, et al. Innervation patterns of autonomic axons in the human endocrine pancreas. Cell Metab. 2011;14(1):45–54.PubMedPubMedCentralCrossRef
162.
Rodriguez-Diaz R, Dando R, Jacques-Silva MC, Fachado A, Molina J, Abdulreda MH, et al. Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming beta cell function in humans. Nat Med. 2011;17(7):888–92.PubMedPubMedCentralCrossRef
163.
Yoshikawa H, Hellström-Lindahl E, Grill V. Evidence for functional nicotinic receptors on pancreatic beta cells. Metabolism. 2005;54(2):247–54.PubMedCrossRef
164.
Somm E, Guérardel A, Maouche K, Toulotte A, Veyrat-Durebex C, Rohner-Jeanrenaud F, et al. Concomitant alpha7 and beta2 nicotinic AChR subunit deficiency leads to impaired energy homeostasis and increased physical activity in mice. Mol Genet Metab. 2014;112(1):64–72.PubMedCrossRef
165.
Ganic E, Singh T, Luan C, Fadista J, Johansson JK, Cyphert HA, et al. MafA-controlled nicotinic receptor expression is essential for insulin secretion and is impaired in patients with type 2 diabetes. Cell Rep. 2016;14(8):1991–2002.PubMedPubMedCentralCrossRef
166.
Duttaroy A, Zimliki CL, Gautam D, Cui Y, Mears D, Wess J. Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice. Diabetes. 2004;53(7):1714–20.PubMedCrossRef
167.
Bokvist K, Eliasson L, Ammälä C, Renström E, Rorsman P. Co-localization of L-type Ca2+ channels and insulin-containing secretory granules and its significance for the initiation of exocytosis in mouse pancreatic β-cells. EMBO J. 1995;14(1):50–7.PubMedPubMedCentralCrossRef
168.
169.
Ishibashi T, Morita S, Kishimoto S, Uraki S, Takeshima K, Furukawa Y, et al. Nicotinic acetylcholine receptor signaling regulates inositol-requiring enzyme 1α activation to protect β-cells against terminal unfolded protein response under irremediable endoplasmic reticulum stress. J Diabetes Investig. 2020;11(4):801–13.PubMedPubMedCentralCrossRef
170.
Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334(6059):1081–6.PubMedCrossRef
171.
Klee P, Bosco D, Guerardel A, Somm E, Toulotte A, Maechler P, et al. Activation of nicotinic acetylcholine receptors decreases apoptosis in human and female murine pancreatic islets. Endocrinology. 2016;157(10):3800–8.PubMedCrossRef
172.
Shikora S, Toouli J, Herrera MF, Kulseng B, Zulewski H, Brancatisano R, et al. Vagal blocking improves glycemic control and elevated blood pressure in obese subjects with type 2 diabetes mellitus. J Obes. 2013;2013:245683.PubMedPubMedCentralCrossRef
173.
Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology. 2003;28(3):542–51.PubMedCrossRef
Metadaten
Titel
Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation
verfasst von
Han Xie
Natesh Yepuri
Qinghe Meng
Ravi Dhawan
Colin A. Leech
Oleg G. Chepurny
George G. Holz
Robert N. Cooney
Publikationsdatum
26.08.2020
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 4/2020
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-020-09584-3

Weitere Artikel der Ausgabe 4/2020

Reviews in Endocrine and Metabolic Disorders 4/2020 Zur Ausgabe

ReviewPaper

The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective

ReviewPaper

Clinical manifestations and management of fatty acid oxidation disorders

ReviewPaper

Review of the veteran affairs diabetes trial: Lessons learned

ReviewPaper

Acromegaly, inflammation and cardiovascular disease: a review

ReviewPaper

Ketotherapy as an epigenetic modifier in cancer

ReviewPaper

Hypothalamus-pituitary-adrenal Axis in Glucolipid metabolic disorders

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise